Gottlieb AB, Armstrong AW, Merola JF, Napoli A, Nowak M, Banerjee S, Lehman T, Mease PJ. Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial. J of Skin [Internet]. 2024Mar.18 [cited 2024Sep.20];8(2):s383. Available from: https://dermsquared.com/skin/article/view/2678